8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions

Patent metadata

Field	Value
Publication number	US-9556175-B2
Application number	US-201615070263-A
Country	US
Kind code	B2
Filing date	Mar 15, 2016
Priority date	Aug 21, 2002
Publication date	Jan 31, 2017
Grant date	Jan 31, 2017

Abstract

The present invention relates to substituted xanthines of general formula

wherein R 1 to R 3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

First claim

What is claimed is:

1. A compound selected from the group consisting of:
(14) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine,
and
(18) 1-(2-{2-[(isopropylcarbonyl)amino]phenyl}-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine,
or a pharmaceutically acceptable salt thereof.

2. A physiologically acceptable salt of a compound according to claim 1 , with inorganic or organic acids or bases.

3. A pharmaceutical composition comprising a pharmaceutically acceptable amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, optionally together with one or more inert carriers and/or diluents.

Assignees

• Boehringer Ingelheim Int

Inventors

• Himmelsbach Frank
• Langkopf Elke
• Eckhardt Matthias
• Mark Michael
• Maier Roland
• Lotz Ralf
• Tadayyon Mohammad

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P13/12

  of the kidneys · CPC title